CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. is a China-focused biopharmaceutical company established in 2012 with its headquarters in the United States. The company's slogan is "To be a global biopharmaceutical company delivering life-changing therapeutics built upon a foundation in China." CANbridge is dedicated to accelerating the development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, specifically focusing on addressing medical needs that are underserved in the region. Notably, CANbridge has established itself as a leader in orphan diseases in China. The company has secured strategic partnerships to develop and commercialize proprietary therapeutics for the treatment of rare genetic diseases. It has an exclusive licensing agreement to commercialize Hunterase®, an enzyme replacement therapy for the treatment of Hunter syndrome, developed by GC Pharma and marketed in more than ten countries worldwide. Additionally, CANbridge has a portfolio in oncology, including exclusive rights to develop and commercialize Puma Biotechnology’s NERLYNX® (neratinib) in greater China, along with rights to other novel candidates. In the latest funding round, CANbridge Pharmaceuticals Inc. secured a substantial $43.00M Series E investment on 01 December 2020. The investors in this round included Casdin Capital, RA Capital Management, Bulldog Innovation Group, LYFE Capital, 华大共赢 BGI COWIN, Summer Capital, SPDB International Holdings, Hudson Bay Capital Management, Hangzhou Zhiyan Dongli Jishu Management Consulting, and DNV capital. This significant investment is poised to propel the company's efforts in developing and bringing life-changing therapeutics to the market, aligning with its vision to make a meaningful impact in the biopharmaceutical industry both regionally and globally.